Trial data explain failure of invasive E coli vaccine
Janssen and Sanofi's ExPEC9V vaccine trial for invasive E. coli disease was discontinued after showing 14.6% efficacy, failing to protect against infections despite a strong immune response. The Lancet study suggests the vaccine's immunity may not have been sufficient. Further analysis is needed to understand the failure.
How this was made
The 30-second read
Why it matters
The disclosed efficacy of 14.6% is far below the threshold for regulatory approval, signaling a likely abandonment or major redesign of the program.
Market read
First public disclosure of the trial’s lack of efficacy, prompting reassessment of vaccine pipeline valuations for both JNJ and SNY.
What to watch
The trial still demonstrated safety and strong antibody titers, which could support future product iterations.
Background
The ExPEC9V vaccine targeted extraintestinal pathogenic E. coli, a leading cause of sepsis in older adults. The trial enrolled >17,000 participants across 20 countries.
Ticker impact
Sanofi’s partner Janssen reported the ExPEC9V vaccine failed to meet its primary endpoint in the phase 3 E.mbrace study.
likely pressure as the market adjusts expectations for the vaccine’s commercial potential
Sanofi’s infectious‑disease segment loses a potential product, prompting a reassessment of growth outlook.
Market effects
The failure may dampen investor enthusiasm for the broader infectious‑disease vaccine sector.
Limited to U.S. and European biotech investors tracking Janssen and Sanofi.
Modest; impacts global vaccine development pipelines but does not affect macro trends.
Counterpoint
Some analysts may see the modest immune response as a stepping stone for next‑generation candidates.
Key entities
- CompanyJanssen Pharmaceuticals
Johnson & Johnson’s pharmaceutical arm, co‑developer of ExPEC9V.
- CompanySanofi
French pharma partner in the ExPEC9V vaccine development.
